Mark Exley, Ph.D. Head of Cellular Immunology
Mark Exley, Ph.D. leads cellular immunology at AgenTus, and is an expert on the biology and clinical exploitation of NKT and other immune cells.
He co-developed anti-NKT monoclonal antibodies used in clinical trials published in 2017.
Dr. Exley’s areas of research have included
- immunity to cancers: natural anti-tumor immunity and how to optimize responses directly and through vaccines
- protective versus inflammatory immune responses to acute and chronic viral infections
- cells involved in suppressing graft-versus-host disease, obesity-associated and other inflammations
Dr. Exley has published over 120 mostly peer-reviewed articles in scientific journals, as well as reviews and book chapters, and serves as Associate Editor of Clin. Immunol.
He has received numerous research awards and grants from federal and other agencies.
Dr. Exley was Faculty at Harvard Medical School, where he was co-founder of NKT Therapeutics Inc., and Professor at University of Manchester, UK.
He retains honorary appointments at both institutions.
Dr. Exley completed his post-doctoral fellowship at the Dana Farber Cancer Institute, Harvard Medical School and was a Scientist at Immulogic Inc.
Dr. Exley received his BS from Imperial College, London, MS from King’s College, London and his Ph.D. from the Institute of Cancer Research, London.